Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020377 citationsJournal Articlehybrid Open Access

Authors

Jennifer K. Litton · The University of Texas MD Anderson Cancer Center

Sara A. Hurvitz · University of California, Los Angeles

Lida A. Mina · The University of Texas MD Anderson Cancer Center

Hope S. Rugo · University of California, San Francisco

Ki Hoon Lee · Seoul National University Hospital

Anthony Gonçalvès · Institut Paoli-Calmettes

Sami Diab

Abstract

In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.

Topics & Keywords

PARP inhibition in cancer therapy Advanced Breast Cancer Therapies BRCA gene mutations in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Oncology

Volume 31, Issue 11, pp. 1526-1535

DOI: 10.1016/j.annonc.2020.08.2098

Field-Weighted Citation Impact: 18.10